TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14727149

Group type: EXPERIMENTAL
Intervention: Full course of oral levofloxacin (500 mg q12 h)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intravenous-to-oral sequential therapy (intravenous ceftriaxone 2 g q24 h with or without clarithromycin 500 mg q12 h followed by oral beta-lactam)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Full course of oral levofloxacin
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intravenous-to-oral sequential therapy
Number of subjects: 129
Study: 11461805

Group type: EXPERIMENTAL
Intervention: Study drug (possibly at different dosages)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or pseudo-placebo control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose of the study drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose of the study drug
Number of subjects: 0
Study: 9066005

Group type: EXPERIMENTAL
Intervention: Bradykinin infusion in ACEI-treated patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bradykinin infusion in placebo-treated patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bradykinin infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ACEI treatment
Number of subjects: 17
Study: 7526067

Group type: EXPERIMENTAL
Intervention: 1 mg idrapril
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg idrapril
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 25 mg idrapril
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg idrapril (oral)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg captopril
Number of subjects: 8

Group type: COMPARATOR
Intervention: oral placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: intravenous placebo
Number of subjects: 8
Study: 3443046

Group type: EXPERIMENTAL
Intervention: Stepronine-lysine salt treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28856925

Group type: EXPERIMENTAL
Intervention: Bone–patellar tendon–bone (BTB) grafts
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hamstring tendon (HT) grafts
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups (BTB and HT)
Number of subjects: 100
Study: 26754182

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to the PC 6 acupuncture point for 14 seconds (300 mW, energy density 4 J/cm²)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (simulated laser application)
Number of subjects: 25
Study: 24943987

Group type: EXPERIMENTAL
Intervention: Intervention group (community pharmacist intervention)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 395
Study: 23286297

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimized acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19399583

Group type: EXPERIMENTAL
Intervention: Preoperative supplement of carbohydrate and branched-chain amino acid-enriched nutrient mixture
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no preoperative supplementation)
Number of subjects: 26
Study: 17976963

Group type: EXPERIMENTAL
Intervention: Moderate beer consumption for 30 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Alcohol abstention for 30 days
Number of subjects: 57
Study: 15871443

Group type: EXPERIMENTAL
Intervention: Environmental tobacco smoke exposure (ETS)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No environmental tobacco smoke exposure (unexposed)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Non-asthmatic children
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Asthmatic children
Number of subjects: 57
Study: 12529343

Group type: EXPERIMENTAL
Intervention: Platinum-based adjuvant chemotherapy
Number of subjects: 925

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 925
Study: 10738097

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR live oral cholera vaccine
Number of subjects: 67508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67508
Study: 8855176

Group type: EXPERIMENTAL
Intervention: Standard regimen, 3 MU three times per week for 6 months
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Higher dose, 6 MU three times per week
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Extended duration, 12 months vs. 6 months at 3 MU
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Extended duration, 12 months vs. 6 months at 6 MU
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3 months of interferon treatment for acute hepatitis C
Number of subjects: 21
Study: 1891951

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine (PRP-D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine (PRP-D or HbOC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugate vaccines (PRP-D, HbOC, PRP-T)
Number of subjects: 0
Study: 6671926

Group type: EXPERIMENTAL
Intervention: Amoxycillin (582 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ampicillin from bacampicillin (800 mg)
Number of subjects: 5
Study: 31444999

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg daily
Number of subjects: 15
Study: 30196134

Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey results indicating practice change
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose and fractionation schedule
Number of subjects: 0
Study: 26924549

Group type: EXPERIMENTAL
Intervention: BioHyalux
Number of subjects: 88

Group type: COMPARATOR
Intervention: Restylane
Number of subjects: 88
Study: 25286174

Group type: EXPERIMENTAL
Intervention: Parent-based HIV prevention intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study: 22424025

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin (concomitant treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19568958

Group type: EXPERIMENTAL
Intervention: Irinotecan combined with 5-fluorouracil and folinic acid (IF arm)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Cisplatin with 5-fluorouracil (CF arm)
Number of subjects: 333
Study: 17499999

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 5 mg kg(‐1) after induction of anaesthesia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline as placebo
Number of subjects: 39
Study: 15020614

Group type: EXPERIMENTAL
Intervention: Fotemustine 100 mg/m2 weekly for 3 weeks
Number of subjects: 229

Group type: COMPARATOR
Intervention: DTIC 250 mg/m2/d for 5 consecutive days every 4 weeks
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Fotemustine
Number of subjects: 229

Group type: COMPARATOR
Intervention: DTIC
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Fotemustine and DTIC
Number of subjects: 229
Study: 12499030

Group type: EXPERIMENTAL
Intervention: Desogestrel/Ethinyl Estradiol (DSG/EE)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 10075217

Group type: EXPERIMENTAL
Intervention: Routine iron and folate supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemoglobin determination late in pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for asymptomatic bacteriuria by urine culture or dipstick
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serologic screening and treatment of syphilis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obtaining a history of difficult labor in multipara or height in nullipara
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External cephalic version at term
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine measurement of fundal height
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction of maternal physical strain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnosis and treatment of tuberculosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malaria prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adequate tetanus immunization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antenatal and perinatal Zidovudine in HIV-positive mothers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One vaginal examination during pregnancy
Number of subjects: 0
Study: 7645180

Group type: EXPERIMENTAL
Intervention: proxodolol
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: proxodolol combined with pilocarpine and/or klofelin
Number of subjects: 105
Study: 2650698

Group type: EXPERIMENTAL
Intervention: High fish intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low saturated fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eating fish once or twice a week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low level of fish consumption
Number of subjects: 0
Study: 322693

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17‐butyrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurandrenolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study: 30946156

Group type: EXPERIMENTAL
Intervention: lifestyle diet and exercise intervention
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: increased physical activity (walking an additional 10,000 steps per day)
Number of subjects: 107
Study: 28351156

Group type: EXPERIMENTAL
Intervention: Exercise + Phytoestrogen (EX + PHY)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Exercise + Placebo (EX + PL)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (EX + PHY and EX + PL)
Number of subjects: 31
Study: 25939436

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone for 21 days in addition to conventional heart failure medication
Number of subjects: 110
Study: 23435927

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin(®)), ≤ 50 U per eye, flexible doses, flexible injection intervals (minimum of 6 weeks)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin(®))
Number of subjects: 102
Study: 21796089

Group type: EXPERIMENTAL
Intervention: Fascial Manipulation© technique (3 sessions of 30 minutes each, every five days for two weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional approach (10 sessions of 30 minutes each, five days a week for two consecutive weeks of neck exercises plus mobilization)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fascial Manipulation© technique
Number of subjects: 18
Study: 19181730

Group type: EXPERIMENTAL
Intervention: Antenatal peer support worker service (1140 women)
Number of subjects: 2511

Group type: COMPARATOR
Intervention: Standard care (1371 women)
Number of subjects: 2511
Study: 17315084

Group type: EXPERIMENTAL
Intervention: Milk supplement
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 139
Study: 15038622

Group type: EXPERIMENTAL
Intervention: More intensive BP-lowering group (home systolic BP < 125 mmHg and diastolic < 80 mmHg)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Less intensive BP-lowering group (home systolic/diastolic BP within the range 134-125/84-80 mmHg)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Ca-A)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor antagonist (ARB)
Number of subjects: 546
Study: 11755558

Group type: EXPERIMENTAL
Intervention: No bladder flap formation (study group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Bladder flap formation (control group)
Number of subjects: 102
Study: 9646426

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 3 g
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Placebo/Azathioprine (PLA/AZA)
Number of subjects: 1493
Study: 7837014

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Healon) used during adjustable suture surgery.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no hyaluronic acid) during adjustable suture surgery.
Number of subjects: 28
Study: 3414406

Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg) and hydrochlorothiazide (50 mg) (Moduretic)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study: 31922432

Group type: EXPERIMENTAL
Intervention: IV dexamethasone (0.2 mg/kg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: IV lidocaine (1 mg/kg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: IV dexamethasone (0.2 mg/kg) and IV lidocaine (1 mg/kg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 31233407

Group type: EXPERIMENTAL
Intervention: Fentanyl (10 μg/kg intravenously)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonfentanyl (nitrous oxide and D-tubocurarine without fentanyl)
Number of subjects: 16
Study: 28611110

Group type: EXPERIMENTAL
Intervention: Supervised high-intensity progressive resistance training and impact loading programme for 8 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supervised machine-based isometric exercise training programme using the bioDensity system for 8 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised high-intensity progressive resistance training and impact loading programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supervised machine-based isometric exercise training programme using the bioDensity system
Number of subjects: 0
Study: 26281053

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (1 mg twice daily) via transnasal nebulization for one week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral prednisone (24 mg QD)
Number of subjects: 50
Study: 23374898

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg (R10)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Rosuvastatin 2.5 mg/day combined with Ezetimibe 10 mg/day (R2.5/E10)
Number of subjects: 46
Study: 21474637

Group type: EXPERIMENTAL
Intervention: 8-week multidisciplinary group therapy program consisting of physical exercise and educational program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 34
Study: 18061276

Group type: COMPARATOR
Intervention: Pharmacotherapy (PhT)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Short‐term psychodynamic supportive psychotherapy (SPSP)
Number of subjects: 141
Study: 16390499

Group type: EXPERIMENTAL
Intervention: Testoderm TTS body patch (5 mg/day, n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo patch (n = 19)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Testoderm TTS body patch (5 mg/day, n = 20) and Placebo patch (n = 19)
Number of subjects: 39
Study: 14606111

Group type: EXPERIMENTAL
Intervention: Garlicin prevention group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fluconazole (low dosage) prevention group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 10929446

Group type: EXPERIMENTAL
Intervention: 1 microgram alfacalcidol plus 5000 mg calcium (group A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: 1000 IU vitamin D plus 500 mg calcium (group B)
Number of subjects: 85
Study: 8761391

Group type: EXPERIMENTAL
Intervention: Gd‐DTPA enhancement
Number of subjects: 25
Study: 1563531

Group type: EXPERIMENTAL
Intervention: tolrestat 200 mg once daily for 6 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 4003919

Group type: EXPERIMENTAL
Intervention: Combined therapy (theophylline + salbutamol)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 25
Study: 31978429

Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroids (ICS)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Low-dose inhaled corticosteroids (ICS)
Number of subjects: 463
Study: 29991209

Group type: EXPERIMENTAL
Intervention: Multi-fractionated Hypericum perforatum (M-Hp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Hypericum perforatum (C-Hp)
Number of subjects: 0
Study: 27565426

Group type: EXPERIMENTAL
Intervention: Antrodia cinnamomea (AC) 20 ml twice daily for 30 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 25438877

Group type: EXPERIMENTAL
Intervention: Financial reward for each accepted antipsychotic medication depot (M4M)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Treatment as usual without financial rewards
Number of subjects: 168
Study: 22612986

Group type: EXPERIMENTAL
Intervention: Tracheotomy tube diameter 6.5 mm
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tracheotomy tube diameter 8 mm
Number of subjects: 10
Study: 20537455

Group type: EXPERIMENTAL
Intervention: eGFRs calculated using the 4‐variable isotope‐dilution mass spectrometry (IDMS)‐traceable MDRD Study equation
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: eGFRs calculated using the CKD‐EPI SCysC equation
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: eGFRs calculated using the CKD‐EPI SCr‐SCysC equation
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: Average of 3 consistent mGFRs
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: Average of 2 consistent mGFRs
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: Single reference mGFR
Number of subjects: 1995
Study: 17296986

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging in patients with neuropsychologic deficits
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 12
Study: 15691253

Group type: EXPERIMENTAL
Intervention: Irregularity Index parameters for malignant melanomas
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Irregularity Index parameters for predicting disease status
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Malignant melanoma with irregular border
Number of subjects: 188
Study: 11809987

Group type: EXPERIMENTAL
Intervention: Incremental shuttle walking test (SWT) after combined nebulised salbutamol/ipratropium bromide
Number of subjects: 82

Group type: COMPARATOR
Intervention: Incremental shuttle walking test (SWT) in controls without airflow limitation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Nottingham Extended Activities of Daily Living index (NEADL)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: London Handicap score (LHS)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in 1 second (FEV1)
Number of subjects: 82
Study: 10609815

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 655

Group type: COMPARATOR
Intervention: Diclofenac SR 75 mg twice daily
Number of subjects: 655
Study: 7856783

Group type: EXPERIMENTAL
Intervention: Intervention (smokeless tobacco cessation intervention)
Number of subjects: 518
Study: 2048706

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (preoperative data)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All groups (C)
Number of subjects: 31
Study: 7196564

Group type: EXPERIMENTAL
Intervention: Photocoagulation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DRS xenon technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 31527919

Group type: EXPERIMENTAL
Intervention: Tools of the Mind (Tools)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control group (traditional classes)
Number of subjects: 351
Study: 29446445

Group type: EXPERIMENTAL
Intervention: Lenograstim 5 micro g/kg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Biosimilar filgrastim 10 micro g/kg
Number of subjects: 42
Study: 27098429

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with BCNU (or busulfan) and thiotepa followed by autologous stem cell transplantation (HCT‐ASCT)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional‐dose immuno chemotherapy with rituximab 375 mg/m(2) (d0), dexamethasone 40 mg/d (d1‐3), etoposide 100 mg/m(2)/d (d1‐3), ifosfamide 1500 mg/m(2)/d (d1‐3) and carboplatin 300 mg/m(2) (d1) (R‐DeVIC)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: HCT‐ASCT
Number of subjects: 250

Group type: COMPARATOR
Intervention: R‐DeVIC
Number of subjects: 250
Study: 24465425

Group type: EXPERIMENTAL
Intervention: Progesterone (300 mg daily)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 23234253

Group type: EXPERIMENTAL
Intervention: Nurse-led personalised care intervention
Number of subjects: 0
Study: 20632503

Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament-retained mobile-bearing prosthesis (group A)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Posterior stabilized fixed-bearing prosthesis (group B)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Posterior cruciate ligament-retained mobile-bearing prosthesis (group C)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 73
Study: 17066315

Group type: EXPERIMENTAL
Intervention: Cumulative risk factor model for predicting reading achievement
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Cumulative risk factor model for predicting mathematics achievement
Number of subjects: 494
Study: 16107306

Group type: EXPERIMENTAL
Intervention: aceclofenac-loaded soft capsule (100mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: conventional aceclofenac tablet (100mg)
Number of subjects: 14
Study: 11877640

Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendectomy (LA)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Open Appendectomy (OA)
Number of subjects: 129